With $70 million in hand, Excellergy Inc. is ready to advance its lead candidate for allergic diseases into clinical trials. The series A round was led by Samsara Biocapital with co-investments from Red Tree Venture Capital and Decheng Capital.
Dualitas Therapeutics Inc. exited stealth mode with a $65 million series A investment that was co-led by Versant Ventures and Qiming Venture Partners USA.
Allrock Bio Inc. secured $50 million in a series A round co-led by Versant Ventures and Westlake Biopartners to advance ROC-101, an oral pan-rho-associated protein kinase (ROCK) inhibitor to treat pulmonary arterial hypertension and pulmonary hypertension with interstitial lung disease.
Dualitas Therapeutics Inc. exited stealth mode with a $65 million series A investment that was co-led by Versant Ventures and Qiming Venture Partners USA.
Antiva Biosciences Inc. has developed an intravaginal topical treatment, ABI-2280, for high-risk cervical infections with human papillomavirus (HPV). In a phase Ib/II study, after two weeks of treatment at the highest dose of the DNA polymerase inhibitor, 46% of patients were negative for high-risk HPV at week 12, compared to just 16% of patients treated with placebo.
Leal Therapeutics Inc. is taking advantage of new genetic data that suggest products from metabolic pathways are involved in psychiatric and neurodegenerative diseases.
Singapore-based Immortal Dragons has launched with $40 million under management, mostly from its founder Boyang Wang, with a focus on investing in early stage companies developing treatments to extend life.
Following up on the $175 million it raised in September 2023, Avalyn Pharma Inc. secured an additional $100 million in an oversubscribed series D financing round to support development of its inhaled treatments for pulmonary fibrosis.
Following up on the $175 million it raised in September 2023, Avalyn Pharma Inc. secured an additional $100 million in an oversubscribed series D financing round to support development of its inhaled treatments for pulmonary fibrosis.
Launched out of 5AM Ventures’ 4:59 Initiative, Renasant Bio Inc. has secured $54.5 million in seed funding to support development of treatments for autosomal dominant polycystic kidney disease (ADPKD), a genetic disease caused by mutations in the PKD1 and PKD2 genes, which encode polycystin proteins PC1 and PC2 that come together to form a calcium ion channel vital for kidney function.
